Opportunities and challenges following approval of resmetirom for MASH liver disease

Jeffrey V. Lazarus; Dana Ivancovsky Wajcman; Henry E. Mark; Zobair M. Younossi; Christopher J. Kopka; Nevin Cohen; Meena B. Bansal; Michael Betel; Paul N. Brennan

doi:10.1038/s41591-024-02958-z

Opportunities and challenges following approval of resmetirom for MASH liver disease

Jeffrey V. Lazarus, Dana Ivancovsky Wajcman, Henry E. Mark, Zobair M. Younossi, Christopher J. Kopka, Nevin Cohen, Meena B. Bansal, Michael Betel, Paul N. Brennan

Research output: Contribution to journal › Comment/Debate

Abstract

The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.

Original language	English
Pages (from-to)	3402-3405
Number of pages	4
Journal	Nature Medicine
Volume	30
Issue number	12
Early online date	19 Apr 2024
DOIs	https://doi.org/10.1038/s41591-024-02958-z
State	Published - Dec 2024
Externally published	Yes

Bibliographical note

Publisher Copyright:
© Springer Nature America, Inc. 2024.

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/s41591-024-02958-z

Cite this

@article{61ba5e161e124ec088da23e93d21f175,

title = "Opportunities and challenges following approval of resmetirom for MASH liver disease",

abstract = "The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.",

author = "Lazarus, {Jeffrey V.} and {Ivancovsky Wajcman}, Dana and Mark, {Henry E.} and Younossi, {Zobair M.} and Kopka, {Christopher J.} and Nevin Cohen and Bansal, {Meena B.} and Michael Betel and Brennan, {Paul N.}",

note = "Publisher Copyright: {\textcopyright} Springer Nature America, Inc. 2024.",

year = "2024",

month = dec,

doi = "10.1038/s41591-024-02958-z",

language = "English",

volume = "30",

pages = "3402--3405",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "12",

}

TY - JOUR

T1 - Opportunities and challenges following approval of resmetirom for MASH liver disease

AU - Lazarus, Jeffrey V.

AU - Ivancovsky Wajcman, Dana

AU - Mark, Henry E.

AU - Younossi, Zobair M.

AU - Kopka, Christopher J.

AU - Cohen, Nevin

AU - Bansal, Meena B.

AU - Betel, Michael

AU - Brennan, Paul N.

PY - 2024/12

Y1 - 2024/12

N2 - The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.

AB - The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.

UR - http://www.scopus.com/inward/record.url?scp=85191061514&partnerID=8YFLogxK

U2 - 10.1038/s41591-024-02958-z

DO - 10.1038/s41591-024-02958-z

M3 - Comment/Debate

C2 - 38641752

AN - SCOPUS:85191061514

SN - 1078-8956

VL - 30

SP - 3402

EP - 3405

JO - Nature Medicine

JF - Nature Medicine

IS - 12

ER -

Opportunities and challenges following approval of resmetirom for MASH liver disease

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this